Browse the complete Report on: Poland Pharmaceuticals and Healthcare Report Q4 2010
Browse All Business Monitor International Market Research Reports
Propped up by its large population, Poland has surfaced as one of the most important global emerging markets, with its value in 2009 calculated at PLN30.25bn (US$10.26bn) at retail prices. Over a five-year period, BMI forecasts that pharmaceutical sales in Poland will increase at a compound annual growth rate (CAGR) of 6.7% in zloty terms, or 9.1% in US dollar terms. By absolute value, the market will have grown to PLN41.80bn (US$15.83bn) by 2014, making Poland the ninth-fastest growing market globally.
In BMI’s Pharmaceuticals & Healthcare Business Environment Ratings (BERs) for Emerging Europe in Q410, Poland remains in second place, supported by increased optimism surrounding the country’s market outlook. On a global basis, Poland is 17th of the total of 83 markets surveyed in our pharmaceutical universe. However, the country’s longer-term demographic outlook is relatively challenging, as are some of the current regulatory issues.
Nevertheless, factors such as an educated workforce and lower manufacturing costs will continue to attract foreign players. To this end, in July 2010, Synexus, a UK-based clinical trials company, was reported to be expanding its presence in Poland with a new research centre in the northern city of Gdynia.
This adds to the company's portfolio of facilities across the Central and Eastern Europe (CEE) region, which includes research centres in Bulgaria, Hungary, Austria and Ukraine. In addition to lower operating costs, Synexus and other clinical research organisations (CROs) are also attracted to emerging markets by their large segments of treatment-naïve patients. The clinical trials industry in Poland is already worth around PLN700mn (US$233mn), with the number of Phase IV trials increasing in recent years.
BMI expects the Polish economy to continue expanding at a healthy clip over our ten-year forecast period, with average annual real growth of 3.3% during 2015-2019. Moreover, Poland's solid macroeconomic fundamentals and credible central bank will likely see euro adoption around 2014, underpinning further integration into the EU and thus further facilitating cross-border business. Inflation of less than 3% for most of our forecast period will also mean that the forecast expansion of the pharmaceutical market is mostly based on direct changes in values and volumes of medicines sold. Still, the operating environment for drugmakers - especially of those offering more expensive patented treatments - will remain challenging, given the focus on cost-containment. While the recently announced PLN590mn (US$187mn) injection into the reimbursement budget will provide a degree of optimism to the pharmaceutical industry, the amount is a shadow of the PLN1.5bn (US$476mn) overall cut in the public health expenditure budget for 2010. Nevertheless, threats remain from potential changes to the reimbursement system, the backlog of approvals for innovative drugs and the introduction of company taxation for reimbursed medicines. The local industry has been consolidating, partly as a result of the government’s privatisation initiatives, but also party due to competitive pressures.
About Us
ReportsandReports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.
Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
http://reportsandreports.blogspot.com/
http://reportsandreports.proarticles.co.uk/
http://reportsnreports.wordpress.com/
Original Source : – Pharmaceuticals and Healthcare Market
Buy Now : Market Research Report
Browse All Business Monitor International Market Research Reports
Propped up by its large population, Poland has surfaced as one of the most important global emerging markets, with its value in 2009 calculated at PLN30.25bn (US$10.26bn) at retail prices. Over a five-year period, BMI forecasts that pharmaceutical sales in Poland will increase at a compound annual growth rate (CAGR) of 6.7% in zloty terms, or 9.1% in US dollar terms. By absolute value, the market will have grown to PLN41.80bn (US$15.83bn) by 2014, making Poland the ninth-fastest growing market globally.
In BMI’s Pharmaceuticals & Healthcare Business Environment Ratings (BERs) for Emerging Europe in Q410, Poland remains in second place, supported by increased optimism surrounding the country’s market outlook. On a global basis, Poland is 17th of the total of 83 markets surveyed in our pharmaceutical universe. However, the country’s longer-term demographic outlook is relatively challenging, as are some of the current regulatory issues.
Nevertheless, factors such as an educated workforce and lower manufacturing costs will continue to attract foreign players. To this end, in July 2010, Synexus, a UK-based clinical trials company, was reported to be expanding its presence in Poland with a new research centre in the northern city of Gdynia.
This adds to the company's portfolio of facilities across the Central and Eastern Europe (CEE) region, which includes research centres in Bulgaria, Hungary, Austria and Ukraine. In addition to lower operating costs, Synexus and other clinical research organisations (CROs) are also attracted to emerging markets by their large segments of treatment-naïve patients. The clinical trials industry in Poland is already worth around PLN700mn (US$233mn), with the number of Phase IV trials increasing in recent years.
BMI expects the Polish economy to continue expanding at a healthy clip over our ten-year forecast period, with average annual real growth of 3.3% during 2015-2019. Moreover, Poland's solid macroeconomic fundamentals and credible central bank will likely see euro adoption around 2014, underpinning further integration into the EU and thus further facilitating cross-border business. Inflation of less than 3% for most of our forecast period will also mean that the forecast expansion of the pharmaceutical market is mostly based on direct changes in values and volumes of medicines sold. Still, the operating environment for drugmakers - especially of those offering more expensive patented treatments - will remain challenging, given the focus on cost-containment. While the recently announced PLN590mn (US$187mn) injection into the reimbursement budget will provide a degree of optimism to the pharmaceutical industry, the amount is a shadow of the PLN1.5bn (US$476mn) overall cut in the public health expenditure budget for 2010. Nevertheless, threats remain from potential changes to the reimbursement system, the backlog of approvals for innovative drugs and the introduction of company taxation for reimbursed medicines. The local industry has been consolidating, partly as a result of the government’s privatisation initiatives, but also party due to competitive pressures.
About Us
ReportsandReports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.
Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
http://reportsandreports.blogspot.com/
http://reportsandreports.proarticles.co.uk/
http://reportsnreports.wordpress.com/
Original Source : – Pharmaceuticals and Healthcare Market
Buy Now : Market Research Report
